SRC and hepatocellular carcinoma: Zhulin Wu 77 et al. studied 207 patients with hepatocellular carcinoma and found that luteolin and quercetin could play a therapeutic role through MAPK, JAK-STAT, and other pathways, and the key targets included SRC, EGFR, VEGFA, PIK3R1 and so on.